ArticleHealth science reports2025
Effect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II-IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing spatiotemporal melatonin delivery from engineered platforms for targeted microenvironment remodeling in peripheral neuropathy.Materials today. Bio · 2026Review
- Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Peripheral neuropathy is a major side effect of oxaliplatin-based chemotherapy. The aim of this placebo-controlled double-blind randomized study was to evaluate the effect of melatonin on prevention of oxaliplatin induced peripheral neuropathy (OXIPN) in patients receiving oxaliplatin for colorectal cancer. Methods: Patients with stage II-IV colorectal cancer, who were to receive oxaliplatin-based chemotherapy, were enrolled according to the inclusion criteria and randomly assigned to take either melatonin (20 mg/day) or placebo, during chemotherapy and 1 month after. Neuropathy was assessed by several patient- and physician-based reports, including the National Cancer Institute Common Terminology Criteria for Adverse Events scale (NCI-CTCAE), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20) scale, and oxaliplatin specific scale (OSS). Results: From a total of 80 selected patients, 54 completed the study and were evaluated for the final analysis. Grade 3 neuropathy measured by NCI-CTCAE and OSS in the melatonin arm was significantly lower than the placebo group. But according to EORTC QLQ-CIPN20 scale, no statistically significant difference was observed between the groups. In addition, melatonin use did not improve patients' quality of life compared with placebo. Conclusion: Reduction in grade 3 neuropathy based on NCI-CTCAE and OSS can be of great importance, as it is the higher-grade neuropathy that may lead to functional impairment. Given that to date no medication has been approved for prevention of OXIPN and considering the limited number of patients in the present study, conducting a larger clinical trial on the effect of melatonin may lead to beneficial results in this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.